The cost for the cure

Alzheimer; News from the web:

With the new approved drug for Alzheimer’s there is now the issue of what it will cost and how you’ll be able to afford it.

Biogen said the drug would cost approximately $56,000 for a typical year’s worth of treatment, and it said the price would not be raised for four years.

Medicare is widely expected to cover the treatment. Insurers that offer private or commercial coverage also will pay for care that doctors deem medically necessary.

That may not mean every case, though. If the treatment is proposed for a patient with advanced Alzheimer’s, and research shows the drug isn’t effective in that population, then the insurer may not pay for it.

Read all about it HERE

Finally a cure?

Alzheimer; News from the web:

A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer’s disease rather than relieve symptoms.

But it’s unclear whether the Food and Drug Administration will approve the drug because of persistent questions about its effectiveness.

Read all about it HERE

‘Rejuvenating’ the Alzheimer’s brain

Alzheimer; News from the web:

Alzheimer’s disease is the main cause of dementia and current therapeutic strategies cannot prevent, slow down or cure the pathology. The disease is characterized by memory loss, caused by the degeneration and death of neuronal cells in several regions of the brain, including the hippocampus. Researchers have identified a small molecule that can be used to rejuvenate the brain and counteract the memory loss.

Read all about it HERE

Not 1 but 3 Alzheimer’s?

Alzheimer; News from the web:

What if we think of Alzheimer’s not as one disease, but three separate ones, with overlapping symptoms? Researchers behind a new study say Alzheimer’s encapsulates three distinct molecular conditions, and that a better understanding of each could be a lifeline for failed Alzheimer’s treatment efforts and future research.

Read all about it HERE

A safer Alzheimer’s drug

Alzheimer; News from the web:

In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.

Read all about it HERE

Improving apathy in Alzheimer patients with brain stimulation

Alzheimer; News from the web:

Twenty Veterans with Alzheimer’s disease and apathy took part in a pilot study. Half received repetitive transcranial magnetic stimulation (rTMS), a type of brain stimulation. The others received sham stimulation, basically a placebo.

Through patient and caregiver interviews, the VA team documented “significantly greater improvement” in apathy levels in those who received brain stimulation compared with the control group. The positive effects continued up to three months.

Besides improvements in apathy, the researchers also noted “significantly greater improvement” in memory, attention, and cognition in the rTMS patients compared with the sham treatment group.

Read all about it HERE

FDA does not approve new Alzheimer’s drug

Alzheimer; News from the web:

Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.

The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.

Read all about it HERE

research finds antidepressants may reduce signs of Alzheimer’s

Alzheimer; News from the web:

A new study from a Penn researcher adds to evidence that a class of antidepressant drugs known as SSRIs may reduce production of a key protein found in the brains of people with Alzheimer’s disease. This is evidence, she said, that the drugs could someday be part of a cocktail used to prevent or delay this form of dementia.

www.inquirer.com

Read all about it HERE

Tea, oranges and Broccoli will keep Alzheimer’s at bay

Alzheimer; News from the web:

A new study published in the journal Neurology in January 2020 concludes that increasing the intake of plant flavonols steeply reduces the risk of Alzheimer’s dementia (AD) by up to a half. In other words, AD could be prevented in many people simply by regularly eating and drinking more foods containing these compounds such as tea, oranges and broccoli.

Read all about it HERE

That new medicine for Alzheimer’s

Alzheimer; News from the web:

The biotech world went into a full-on frenzy Tuesday when drug giant Biogen dropped this whopper: The company is reviving its Alzheimer’s drug hopeful, aducanumab, after leaving it for dead all the way back in March. In fact, it’s marching forward with a Food and Drug Administration (FDA) application to approve the drug for certain patients facing cognitive decline.

Read all about it HERE